INTRODUCTION
Anti-citrullinated protein antibodies (ACPA) such as anti-cyclic citrullinated peptide antibodies (aCCPs) are thought to play a pathogenic role in rheumatoid arthritis (RA).
ACPA are highly specific for RA, can be detected several years before the onset of disease, and are associated with disease severity. [1] [2] [3] In animal models it was shown that transfer of monoclonal antibodies recognizing citrullinated fibrinogen or collagen into mice could exacerbate inflammatory arthritis. 4 Furthermore, efficacy of B cell depletion to treat RA using rituximab strongly suggests a pathogenic role of autoantibodies. 5, 6 ACPA, as their name implies, target citrullinated proteins. Formation of citrulline from arginine is mediated by enzymes called peptidyl arginine deiminases (PAD) and may occur during inflammatory conditions. 7 PAD can essentially citrullinate all proteins, depending on the amino acids flanking the arginine. Examples of citrullinated proteins found in the inflamed synovium are fibrinogen, α-enolase and vimentin. [8] [9] [10] [11] So far no dominant epitope has been identified that could be the initial trigger for ACPA formation, although it is clear that the number of different citrullinated proteins recognized by ACPA is limited initially, but increases in time.
This process of epitope spreading occurs prior to diagnosis of RA. 12, 13 Once RA has been diagnosed, the number of recognized epitopes remains stable. 12 Another process reflecting maturation of the antibody response before diagnosis is a rise in avidity of ACPA. The avidity of ACPA rises during the same period at which the epitope spreading takes place, but avidity remains low as compared to viral recall antigens. 14, 15 This could indicate that germinal center formation ceases at a certain time point or that antigens become too abundant to drive further avidity maturation. The latter would fit with the theory of a vicious cycle of epitope spreading. 16 However, the polyclonal nature of the antibody response in RA patients makes it difficult to study characteristics of ACPA's such as cross-reactivity or affinities. In order to better define the ACPA characteristics, we aim to analyze the ACPA responses at the clonal level.
MATERIALS AND METHODS
For detailed materials and methods see supplemental material. In short, for the formation of monoclonal anti-cFib antibodies, B-cells of an RA patient fulfilling the 1987 ACR criteria for RA, 17 were isolated from PBMC's via anti-CD19 Dynabeads. Recombinant anti-cFib1.1 and 1.2 react with cFib1 but not aFib1, and are cross reactive with other citrullinated peptides
The specificity of recombinant anti-cFib1.1 and anti-cFib1.2 was tested in an ELISA for anti-cFib1 peptide. Both monoclonal antibodies were specifically directed against citrullinated cFib1 showing no reactivity with aFib1 peptide (Figure 1 ). Both monoclonal antibodies were also tested for reactivity towards other citrullinated peptides derived from fibrinogen, enolase and vimentin. Anti-cFib1.1 showed cross reactivity towards cFib3 and to a lesser extent towards cEno, cFib2 and cVim. AnticFib1.2 showed cross reactivity towards cEno and cFib2 and to a lesser extent towards cVim and cFib3 (Figure 1 ). This shows that both monoclonal antibodies were citrulline specific and had distinct cross reactivity patterns. Affinity of anti-cFib1.1 and 1.2.
Binding of both antibodies to citrullinated fibrinogen was also assessed with SPR measurements. Both antibodies bind to surface-bound citrullinated fibrinogen, but not native fibrinogen (Figure 2A, B) . Anti-cFib 1.1 showed a complex binding profile and therefore avidity could not be calculated. The complex binding profile 
DISCUSSION
A detailed study of the ACPA antibody response in terms of specificity is severely hampered by its polyclonal nature. We developed a method to clone human monoclonal ACPA resulting in the development of two monoclonal IgG1 antibodies to citrullinated fibrinogen. We showed that these monoclonal antibodies are specific for citrullined fibrinogen peptides, but with distinct (cross-)reactivity patterns towards other citrullinated peptides derived from other proteins. We also showed that these antibodies were derived from different naive B cells that underwent extensive somatic hypermutation. The avidity of citrullinated fibrinogen binding is nevertheless moderate, indicating that citrullinated fibrinogen is not the primary antigen that drove differentiation of these B-cell clones. Notably, the VH of one of the antibodies was derived from V4-b*02, a germline gene that was previously described to be the most prevalent in a phage display library of aCCP antibodies. This study has certain limitations. First, we only cloned two antibodies of one patient and thus, this study should be regarded as a proof of concept study. For a detailed analysis more antibodies of more patients should be cloned. Second, by screening B cells with an ELISA for anti-citrullinated fibrinogen, a selection bias was introduced. In future research it may be possible to screen unselected B-cells for multiple citrullinated peptides with higher sensitivity, for instance with microchipbased assays. This will also allow the cloning of antibodies to other citrullinated proteins. In the present study, we only cloned ACPA for citrullinated fibrinogen, but it would be interesting to see the characteristics of monoclonal antibodies for other citrullinated proteins as well.
In conclusion, we cloned two monoclonal ACPAs derived of an RA patient. Our results indicate that ACPA have distinct cross reactivity patterns and are formed by antigen driven maturation.
SUPPLEMENTARY MATERIAL: DETAILED MATERIALS AND METHODS

Antibody assays
Anti-citrullinated fibrinogen (ACF) antibodies were detected with an ELISA as previously described. 19 In short, IgG depleted fibrinogen was citrullinated using rabbit skeletal muscle PAD and coated on maxisorp microtitre plates. Supernatants were incubated 1:5 for one hour at room temperature on the coated plates and ACF antibodies were detected with horseradish peroxidase conjugated mouse monoclonal antihuman IgG (HRP-IgG) and visualized with 3,3',5,5'tetramethylbenzidine (TMB).
Antibodies were tested for reactivity towards different citrullinated peptides as previously described. 16 In short, sera were incubated on streptavidin plates coated with biotinylated, citrullinated or native peptides. Bound antibodies were detected with HRP-IgG and then visualized with TMB. Reactivity was expressed as difference in optical density (∆OD) between citrullinated and native peptides.
Citrullinated fibrinogen peptide tetramers
Biotinylated citrullinated fibrinogen peptide NEEGFFSACitGHRPLDKK (0.5 mg/mL) was mixed with APC labeled streptavidin (Molecular Probes) (0.5 mg/mL) in PBS/0.1%BSA and incubated on a roller bank over night at 4ºC in the dark.
Tetramers were purified over a bio-spin 30 column (Biorad) according to the manufacturer's protocol. 
Nucleotide sequence analysis
Nucleotide analysis was performed using the international immunogentics information (IMGT) system®
